Physician profile
Brian A Smith
NPI 1992749873
$22,638.27
in general payments reported to CMS, 2019-2025
66 companies · $688 in 2025
The $688 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $966 · 2021: $1,341 · 2022: $2,677 · 2023: $1,677 · 2024: $1,879 · 2025: $688.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,576 · Travel and Lodging: $864 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $804.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,575.92 |
| Travel and Lodging | $863.96 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $804.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $13,309.12 | 2019-2024 | Spravato, Xarelto |
| Alnylam Pharmaceuticals INC. | $1,293.56 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,237.31 | 2021-2025 | |
| Modernatx, INC. | $1,213.96 | 2024 | |
| Abbvie INC. | $829.12 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Pfizer INC. | $364.86 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $355.41 | 2020-2024 | Jardiance |
| Glaxosmithkline, LLC. | $311.81 | 2020-2022 | |
| Lilly USA, LLC | $268.57 | 2019-2025 | Mounjaro, Jardiance |
| Corium, LLC | $232.55 | 2022-2024 | Azstarys |
| Sanofi Pasteur INC. | $212.39 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $200.03 | 2020-2023 | Verquvo, Belsomra, Steglatro |
| Novo Nordisk INC | $193.22 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Grifols USA, LLC | $188.29 | 2020-2025 | Prolastin-C Liquid |
| Teva Pharmaceuticals USA, INC. | $177.22 | 2019-2024 | Austedo Xr |
Show all 63 companies
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.